Hospital Regional Universitario de Malaga | Hospital Civil - Rheumatology Department

Research site

(Unclaimed)

Location

Avenida Arroyo de los Angeles S/N, Malaga, Málaga, Spain

Site insights

Top conditions

Top treatments

Magrolimab

Pembrolizumab

Azacitidine

Amrubicin

Topotecan

Tiragolumab

Venetoclax

Bemarituzumab

Lurbinectedin

Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

24 of 35 total trials

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...

Active, not recruiting

Relapsed/Refractory Small Cell Lung Cancer

Drug: Tarlatamab

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

Locations recently updated

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This stu...

Active, not recruiting

Paroxysmal Nocturnal Hemoglobinuria

Drug: Eculizumab

Drug: Crovalimab

A Study of BAX 888 in Male Adults With Severe Hemophilia A

The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A i...

Active, not recruiting

Hemophilia A

Drug: BAX 888

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this...

Active, not recruiting

ALK+ Advanced NSCLC

Drug: Brigatinib

Drug: Alectinib

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with pr...

Active, not recruiting

Melanoma

Carcinoma, Hepatocellular

Drug: E7386

Drug: Lenvatinib

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Enrolling

Small Cell Lung Cancer

Drug: Topotecan

Drug: Amrubicin

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Ipatasertib

Drug: XL092

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, imp...

Active, not recruiting

Neoplasms by Site

Neoplasms, Nerve Tissue

Drug: Cisplatin

Drug: Pembrolizumab

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participa...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Tiragolumab

Drug: Atezolizumab

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS)...

Enrolling

Relapsing Forms of Multiple Sclerosis

Drug: BIIB091

Drug: DRF

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time thi...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Sunvozertinib

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Drug: Bemarituzumab

Drug: mFOLFOX6

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling

Melanoma

Drug: Cemiplimab

Drug: Placebo

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) (ATHENA-SSc-ILD)

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

Enrolling

Diffuse Cutaneous Systemic Sclerosis

Interstitial Lung Disease

Diagnostic Test: Companion diagnostic ( CDx)

Drug: Tulisokibart

Phase III Study of AK112 for NSCLC Patients

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Enrolling

Non-Squamous Non-small Cell Lung Cancer

Drug: Placebo Injection

Drug: AK112 Injection

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung...

Enrolling

Small Cell Lung Cancer

Drug: Platinum, investigator's choice

Biological: Pembrolizumab 400 mg

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Enrolling

Primary Generalized Epilepsy

Drug: Placebo

Drug: Cenobamate

Locations recently updated